OpenAI 收购 Orchestra Bio，布局 AI 驱动的药物研发
OpenAI 收购 Orchestra Bio，用智能体管药物研发全流程，连生产批次延误都能追踪，医药这块 AI 真开始落地了。
OpenAI 收购了 Orchestra Bio，其智能体可协调药物开发流程，例如追踪一批生产失败会如何推迟临床试验。结合 Rosalind，OpenAI 的目标是把 AI 同时嵌入科学研究和药物上市所需的运营环节。Anthropic 也在同一天发布了类似方向的进展。
Many are asking whether AI investment will pay off. Here's a very good example of where AI is headed and why its more than a bubble:
OpenAI’s acquisition of Orchestra Bio adds agents that coordinate drug development, tracking how problems like a failed manufacturing batch could delay clinical trials. Paired with Rosalind, it shows toward a broader ambition: embedding AI across both scientific research and the operational work needed to bring medicines to patients.
Drug research and disease cure are among the significant fields in which AI extends and will make tremendous progress. Anthropic published something similar today.
